Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period.

28 Oct 2010

deCODE genetics publishes high resolution recombination map of human genome in Nature journal

Scientists from deCODE genetics today publish in Nature the highest resolution recombination map of the human genome yet developed. Recombination is the reshuffling of the genome that occurs in the formation of eggs and sperm: we inherit one version of each chromosome from each of our parents, and create novel blends of the two that we pass on to our offspring.

28 Oct 2010

Diabetes threatens the eyesight of many unsuspecting Americans

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam. As the number of people with Type 2 diabetes rises in the U.S., the CDC projects that the number of adults with diabetic retinopathy will double by the year 2050. Yet 90 percent of diabetic eye disease can be prevented simply by proper regular examinations and treatment and by controlling blood sugar.

27 Oct 2010

Playnormous Video Games receive Creative Child Magazine's 2010 Media of the Year Award

As childhood obesity rates continue to shock the nation, parents and teachers alike are seeking resources to help children learn about making healthier choices. Playnormous, an award-winning producer of research-based health video games and media, puts the power of good health back into the hands of children through creative gameplay. And parents agree. The company's first CD-ROM, Playnormous: Fun For A Change Health Video Games, has been awarded Creative Child Magazine's 2010 Media of the Year Award.

27 Oct 2010

Human haptoglobin gene mutation increases risk of diabetic complications

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a multifactorial disease of complex etiology characterized by the autoimmune destruction of pancreatic beta cells. In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering disease, with virus infection having perhaps the strongest association.

27 Oct 2010

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

27 Oct 2010

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.

26 Oct 2010

Study looks at long-term consequences of heavy smoking on dementia

Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.

26 Oct 2010

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

Repros Therapeutics Inc. today announced it has commenced randomization of subjects into its Phase II Androxal® study in the treatment of type 2 diabetes (T2DM) in men with low testosterone. Low testosterone and T2DM are co-morbid conditions in a significant number of men. The study is being conducted at nine sites across the US including both academic and private practices and will enroll up to 150 patients.

25 Oct 2010

Aortic stiffness seen in obese children

The blood vessels of obese children have stiffness normally seen in much older adults with cardiovascular disease, Dr. Kevin Harris today told the Canadian Cardiovascular Congress 2010, co-hosted by the Canadian Cardiovascular Society and the Heart and Stroke Foundation. The clock is ticking and the shape of the 13 year-old-heart is changing - for the worse.

25 Oct 2010

Two researchers receive European Research Council Starting Grants

Two European Research Council (ERC) Starting Grants worth almost one and a half million euros each over the next five years have been awarded to two researchers from the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and the Charit Universit-tsmedizin, Berlin in Germany.

25 Oct 2010

Diabetes and peripheral artery disease are costly; PAD may spur growth in medical device industry

Diabetes cases in the U.S. are expected to double or triple by 2050, according to a new report by the Centers for Disease Control and Prevention.

25 Oct 2010

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

Diabetes on the rise in Scotland

New reports show that one person is diagnosed with diabetes every 40 minutes in Scotland. This marks the rapid rise in the condition - a trend that is faster that experts had imagined. In the last 1 year another 14,000 Scots were added to those registered with GPs as diabetic.

24 Oct 2010

Australian stem cell line offers fresh approach to diabetes cure

Australian researchers have developed the country’s first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

Eating whole grains and limiting refined grains reduce body fat

People who consume several servings of whole grains per day while limiting daily intake of refined grains appear to have less of a type of fat tissue thought to play a key role in triggering cardiovascular disease and type 2 diabetes, a new study suggests. Researchers at the Jean Mayer USDA Human Nutrition Researcher Center on Aging (USDA HNRCA) at Tufts University observed lower volumes of visceral adipose tissue (VAT) in people who chose to eat mostly whole grains instead of refined grains.

21 Oct 2010

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ profiling service and immunoSEQ Analyzer bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

21 Oct 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

21 Oct 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

deCODE genetics publishes high resolution recombination map of human genome in Nature journal

Diabetes threatens the eyesight of many unsuspecting Americans

Playnormous Video Games receive Creative Child Magazine's 2010 Media of the Year Award

Human haptoglobin gene mutation increases risk of diabetic complications

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Study looks at long-term consequences of heavy smoking on dementia

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

Aortic stiffness seen in obese children

Two researchers receive European Research Council Starting Grants

Diabetes and peripheral artery disease are costly; PAD may spur growth in medical device industry

Arena's NDA receives Complete Response Letter for lorcaserin

Diabetes on the rise in Scotland

Australian stem cell line offers fresh approach to diabetes cure

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Eating whole grains and limiting refined grains reduce body fat

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in